Holen Sie sich die Stockscreener-App
0.8255
4.92%
-0.0425
Schlusskurs vom Vortag:
$0.868
Offen:
$0.8775
24-Stunden-Volumen:
786.16K
Relative Volume:
0.76
Marktkapitalisierung:
$73.73M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-23.49M
KGV:
-2.4018
EPS:
-0.3437
Netto-Cashflow:
$-24.59M
1W Leistung:
+38.80%
1M Leistung:
-19.87%
6M Leistung:
-46.41%
1J Leistung:
+133.00%
1-Tages-Spanne:
$0.8252
$0.8999
1-Wochen-Bereich:
$0.5948
$0.96
52-Wochen-Spanne:
$0.2223
$3.83
Cognition Therapeutics Inc Stock (CGTX) Company Profile
Firmenname
Cognition Therapeutics Inc
Sektor
Branche
Telefon
412-481-2210
Adresse
2500 WESTCHESTER AVE, PURCHASE
Compare CGTX vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
0.8252 | 77.56M | 0 | -23.49M | -24.59M | -0.3437 |
VRTX
Vertex Pharmaceuticals Inc
|
433.59 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
762.90 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.75 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.75 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
164.04 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2024-07-30 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-11-03 | Eingeleitet | B. Riley Securities | Buy |
| 2021-11-03 | Eingeleitet | Oppenheimer | Outperform |
Cognition Therapeutics Inc Aktie (CGTX) Neueste Nachrichten
Fed Meeting: What is the PEG ratio of Cognition Therapeutics Inc2026 Outlook & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
CGTX Technical Analysis & Stock Price Forecast - Intellectia AI
CGTX Should I Buy - Intellectia AI
Cognition Therapeutics plans late-stage trial for dementia drug By Investing.com - Investing.com Australia
Cognition Therapeutics plans late-stage trial for dementia drug - investing.com
Cognition Therapeutics CEO Issues Letter to Shareholders - globenewswire.com
Q1 Earnings Forecast for CGTX Issued By HC Wainwright - MarketBeat
Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation - Sahm
Cognition Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Cognition Therapeutics (NASDAQ:CGTX) Receives Buy Rating from Chardan Capital - MarketBeat
Cognition Therapeutics posts narrower 2025 loss, eyes DLB trial By Investing.com - Investing.com South Africa
Cognition Therapeutics Reports 2025 Financial Results and Advances Zervimesine for DLB Psychosis and Alzheimer’s Clinical Trials - Minichart
Cognition Therapeutics Inc (CGTX) Q4 2025 Earnings Call Highlights: Promising Developments in ... By GuruFocus - Investing.com Canada
Cognition Therapeutics Advances Zervimesine (CT1812) for Alzheimer’s and Dementia—Clinical Results, Pipeline, and Strategic Overview - Minichart
Cognition Therapeutics Highlights 2025 Results, Zervimesine Progress - TipRanks
Cognition Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Earnings Call Summary | Cognition Therapeutics(CGTX.US) Q4 2025 Earnings Conference - 富途牛牛
Cognition Therapeutics Q4 Earnings Call Highlights - MarketBeat
Cognition Therapeutics (NASDAQ:CGTX) Posts Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Earnings call transcript: Cognition Therapeutics Q4 2025 shows reduced losses - Investing.com
Cognition Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
CGTX: Zervimesine advances toward DLB psychosis registration, with strong data and solid cash position - TradingView
Earnings call transcript: Cognition Therapeutics Q4 2025 shows reduced losses By Investing.com - Investing.com South Africa
CGTX: Zervimesine advances for DLB psychosis with strong data, regulatory focus, and improved 2025 financials - TradingView
Cognition Therapeutics posts narrower 2025 loss, eyes DLB trial - Investing.com
COGNITION THERAPEUTICS ($CGTX) Releases Q4 2025 Earnings - Quiver Quantitative
Cognition Therapeutics 10-K: Net loss $23.5M, EPS $(0.32) - TradingView
Zervimesine pipeline and grant backing at Cognition (NASDAQ: CGTX) - Stock Titan
Cognition Therapeutics (NASDAQ: CGTX) narrows 2025 loss, funds into Q2 2027 - Stock Titan
Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update - The Manila Times
Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical ... - Caledonian Record
Cognition Therapeutics (CGTX) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Cognition Therapeutics Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Zervimesine Demonstrates Symptom Slowing in Phase 2 SHIMMER Trial for Dementia With Lewy Bodies - NeurologyLive
Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results - The Globe and Mail
Cognition presents data on dementia drug zervimesine at conference By Investing.com - Investing.com South Africa
CGTX PE Ratio & Valuation, Is CGTX Overvalued - intellectia.ai
Cognition presents data on dementia drug zervimesine at conference - Investing.com
Cognition Therapeutics Presents Evidence of Zervimesine's Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026 - Bitget
Cognition Therapeutics Presents Promising Phase 2 Results of Zervimesine for Dementia with Lewy Bodies at AD/PD 2026 Conference - Quiver Quantitative
Cognition Therapeutics Presents Evidence of Zervimesine’s - GlobeNewswire
Cognition Therapeutics (CGTX) Stock Analysis Report | Financials & Insights - Benzinga Japan
Aug Intraday: Can Cognition Therapeutics Inc lead its sector in growthQuarterly Risk Review & Safe Entry Point Identification - baoquankhu1.vn
MACD Signal: What is the dividend yield of Cognition Therapeutics IncDividend Hike & AI Based Trade Execution Alerts - baoquankhu1.vn
Cognition Therapeutics shifts focus to DLB psychosis treatment By Investing.com - Investing.com Australia
Cognition Therapeutics shifts focus to DLB psychosis treatment - Investing.com Nigeria
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis - Bitget
Cognition Therapeutics Advances Zervimesine for DLB Psychosis - TipRanks
Finanzdaten der Cognition Therapeutics Inc-Aktie (CGTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):